Risperdal News

According to Johnson & Johnson’s 2016 annual report, as of January 1, 2017, 18,500 lawsuits have been filed against the company.  The lawsuits are alleging injuries due to the use of the antipsychotic drug Risperdal. In spite of facing numerous lawsuits, and a podcast series […]

A recent study suggests that lowering the dose of the antipsychotic drug Risperdal could reduce the severity of side effects associated with the medication, such as gynecomastia. The study, published in December 2016 in BMC Psychiatry, involved 374 schizophrenia patients who were randomly assigned to […]

Johnson & Johnson settled the seventh Risperdal case scheduled to go before a jury in Philadelphia’s mass tort program on January 6, just three days before the trial was to begin. The latest lawsuit involved a New York man who alleged that he developed gynecomastia […]

In an attempt to overturn the largest award thus far to come out of the Risperdal mass tort program in Philadelphia, Janssen Pharmaceuticals has filed a list of alleged errors it contends that the trial court made during the A.Y. v. Janssen Pharmaceuticals case. The […]

A lawsuit brought by the Kentucky Attorney General alleging that Janssen Pharmaceuticals, the manufacturer of the antipsychotic drug Risperdal, marketed the medication as an appropriate treatment for dementia in non-schizophrenic elderly patients has been settled for $15.5 million. According to court documents, Janssen Pharmaceuticals even […]

South Carolina Attorney General Alan Wilson announced last month that settlement had finally been reached with Ortho-McNeil-Janssen Pharmaceuticals in the state’s Risperdal case, ending a nine-year-long legal battle. The end came when the U.S. Supreme Court denied Janssen’s attempt to get a $124 million Risperdal […]